Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal

Lots of companies are working to bulk up in the cancer field--but not BioMarin ($BMRN). Buckling down on rare diseases, the company is out-licensing its Phase III PARP inhibitor to Medivation ($MDVN) for $410 million up front, with another $160 million in milestones. The prospect--talazoparib--entered Phase III back in 2013 for advanced breast cancer among patients with BRCA 1 or BRCA 2 mutations, and Medivation is hoping to add it to a marketed portfolio that already includes the successful prostate cancer pill Xtandi. More

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.